Moderna, the US biotech company, is in late stage talks with the government about investing in UK research and manufacturing and collaborating with the NHS on clinical trials.
The Boston-based start-up — which shot to prominence with its mRNA Covid-19 vaccine — is close to agreeing a significant investment, according to people familiar with the matter.
If concluded, the deal would be a “key element” of the UK’s post-Brexit strategy to become a global hub for the life sciences, one of the people said.
您已阅读16%（504字），剩余84%（2594字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。